Clinical trial · Interventional
Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma
Effects of Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma: a Prospective,Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prognosis of small liver cancer (≤5 cm) with stereotactic body radiotherapy (SBRT) is encouraging, the 1-year local control rate has been reported to be 95-100%, 3-year local control rate about 91%, and 3-year overall survival rate around 70%. So far, there is no randomized controlled study comparing SBRT and surgical treatment for early-stage liver cancer. It is hoped that this study will further compare the efficacy of SBRT and surgery for early stage liver cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatectomy | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Stereotactic Body Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laparoscopic hepatectomy (surgery) | Procedure | — | UNRESOLVED |
| stereotactic body radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- group A
- description
- laparoscopic hepatectomy (surgery)
- interventionNames
- Procedure: laparoscopic hepatectomy (surgery)
- type
- EXPERIMENTAL
- label
- group B
- description
- stereotactic body radiotherapy (SBRT)
- interventionNames
- Radiation: stereotactic body radiotherapy
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- From the date of surgery or the first fraction of SBRT until the date of first progression (local or distant), assessed up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18 years old and above. 2. Clinical or pathological diagnosis of hepatocellular carcinoma, initial treatment (without surgery, radiotherapy, chemotherapy or targeted therapy). 3. Early-stage hepatocellular carcinoma meeting the Milan criteria: single lesion ≤ 5cm, or tumor number ≤ 3, maximum diameter ≤ 3cm, no major vascular invasion of portal vein, hepatic vein, inferior vena cava, no bile duct invasion, no lymph node and extrahepatic metastasis. 4. No serious blood system, heart, lung, liver, kidney dysfunction and immune deficiency. 5. The neutrophil count is at least 1.0\*10\^9/ml, and the platelet count is at least 50\*10\^9/ml. Hemoglobin is at least 80g/L. 6. Men or women with fertility are willing to take contraceptive measures during the trial. 7. Eastern Cooperative Oncology Group score 0-1 points. 8. Expected survival period \> 3 months. 9. Voluntary participation and signing of informed consent. Exclusion Criteria: 1. Patients who have undergone chemoradiation or targeted therapy for liver cancer. 2. Recent hematemesis due to portal hypertension. 3. Child-Pugh score ≥10 points. 4. Total bilirubin\>70umol/L, aspartate aminotransferase (ALT), alanine aminotransferase (AST) exceed the upper limit of normal 3 times. 5. who was considered unsuitable for surgery after hepatobiliary and pancreas multidisciplinary treatment（MDT） meeting. 6. Patients undergoing major surgery within 1 month of study initiation 7. Patients with previous history of malignancy (excludes tumor-free survival after treatment of basal cell carcinoma of the skin and carcinoma of the cervix in situ for more than 3 years) 8. Researchers consider it inappropriate to participate in the test
References
Publications (0)
Data not yet available